[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2016001096A - Sales de dasatinib en forma amorfa. - Google Patents

Sales de dasatinib en forma amorfa.

Info

Publication number
MX2016001096A
MX2016001096A MX2016001096A MX2016001096A MX2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A
Authority
MX
Mexico
Prior art keywords
salts
dasatinib
amorphous form
relates
salt
Prior art date
Application number
MX2016001096A
Other languages
English (en)
Inventor
Martin Szelagiewicz
Fritz Blatter
Tiziana Chiodo
Andreas Hafner
Tobias Hintermann
Beate Salvador
Bernd Siebenhaar
Marcus Vossen
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of MX2016001096A publication Critical patent/MX2016001096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención principalmente se refiere a sales de Dasatinib, en donde las sales están en forma amorfa. Las sales descritas en este documento comprenden un catión de un compuesto de fórmula 1 (ver Fórmula) y un anión de un segundo compuesto seleccionado del grupo que consiste en ácido glutárico, ácido nicotínico y sacarina. La invención se refiere en forma adicional a composiciones farmacéuticas que comprenden dicha sal. Además, la invención se refiere a procesos para preparar dichas sales. La invención se refiere a varios aspectos del uso de dicha sal o composición farmacéutica para tratar una enfermedad.
MX2016001096A 2013-07-25 2014-07-22 Sales de dasatinib en forma amorfa. MX2016001096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13178015 2013-07-25
PCT/EP2014/065674 WO2015011119A2 (en) 2013-07-25 2014-07-22 Salts of dasatinib in amorphous form

Publications (1)

Publication Number Publication Date
MX2016001096A true MX2016001096A (es) 2016-04-25

Family

ID=48832837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001096A MX2016001096A (es) 2013-07-25 2014-07-22 Sales de dasatinib en forma amorfa.

Country Status (10)

Country Link
US (1) US9884857B2 (es)
EP (1) EP3024831A2 (es)
JP (1) JP6370377B2 (es)
KR (1) KR101831535B1 (es)
CN (1) CN105377842A (es)
AU (1) AU2014295143B9 (es)
CA (1) CA2917209A1 (es)
MX (1) MX2016001096A (es)
RU (1) RU2655435C2 (es)
WO (1) WO2015011119A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017000304B1 (pt) 2014-07-08 2021-06-29 BASF Agro B.V. Processo para a preparação dos compostos de fórmula ii
DK3294700T3 (da) 2015-05-08 2020-04-14 Basf Agro Bv Fremgangsmåde til fremstilling af limonen-4-ol
CN107635982A (zh) 2015-05-08 2018-01-26 巴斯夫农业公司 制备萜品油烯环氧化物的方法
DK3472139T3 (da) 2016-06-15 2021-06-28 Basf Agro Bv Fremgangsmåde til epoxidering af en tetrasubstitueret alken
WO2017215928A1 (en) 2016-06-15 2017-12-21 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
CN107501305B (zh) * 2017-09-26 2019-04-05 玉林师范学院 一种达沙替尼-铜(ii)配合物及其合成方法和应用
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
CN115192540A (zh) 2018-06-15 2022-10-18 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CA3168667A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
CA3172749A1 (en) * 2020-03-30 2021-10-07 Lois B. ROSENBERGER Pediatric formulation of tyrosine kinase inhibitors
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
WO2024186764A1 (en) * 2023-03-03 2024-09-12 Aems Corp. Sanitizing composition, methods and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2312860C2 (ru) 1999-04-15 2007-12-20 Бристол-Маерс Сквибб Компани Циклические ингибиторы протеинтирозинкиназ
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
EP1937270A1 (en) * 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
PL2508523T5 (pl) 2007-10-23 2020-08-10 Teva Pharmaceutical Industries Ltd. Odmiany polimorficzne dasatynibu i sposób ich wytwarzania
WO2010062715A2 (en) 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
CN102030745B (zh) 2010-11-26 2012-05-09 江苏先声药物研究有限公司 Dasatinib溶剂合物及其制备方法
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
CN102898424A (zh) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 达沙替尼新的多晶型物及其制备方法
CA2844014A1 (en) 2011-08-30 2013-03-07 Basf Se Co-crystals of cyprodinil and dithianon
MX353548B (es) * 2011-11-29 2018-01-18 Ono Pharmaceutical Co Clorhidrato derivado de purinona.
CN102429880B (zh) * 2011-11-29 2014-10-15 上海创诺制药有限公司 一种达沙替尼片
US8796481B2 (en) 2011-12-30 2014-08-05 Basf Se Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine
CN104379582A (zh) 2012-06-15 2015-02-25 巴斯夫欧洲公司 包含达沙替尼和所选择的共晶体形成剂的多组分晶体
EP2864313A1 (en) 2012-06-22 2015-04-29 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
EP2880019B1 (en) 2012-08-06 2016-07-13 Basf Se Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof
MX2015004947A (es) 2012-10-19 2016-02-22 Basf Se Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
JP2016510295A (ja) 2012-12-20 2016-04-07 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ グラフェン材料のエッジハロゲン化
BR112015020194A2 (pt) 2013-03-07 2017-07-18 Basf Se co-cristais, processo para a preparação dos co-cristais, formulação agrícola, métodos para controle de pragas, para melhoria da saúde das plantas e para a proteção de material de propagação de planta contra pragas e material de propagação de planta

Also Published As

Publication number Publication date
JP2016525528A (ja) 2016-08-25
EP3024831A2 (en) 2016-06-01
KR101831535B1 (ko) 2018-02-22
WO2015011119A2 (en) 2015-01-29
AU2014295143B9 (en) 2017-03-23
US20160168142A1 (en) 2016-06-16
RU2655435C2 (ru) 2018-05-29
AU2014295143B2 (en) 2017-03-16
KR20160025573A (ko) 2016-03-08
JP6370377B2 (ja) 2018-08-08
RU2016106124A (ru) 2017-08-30
US9884857B2 (en) 2018-02-06
AU2014295143A1 (en) 2016-02-11
CN105377842A (zh) 2016-03-02
WO2015011119A3 (en) 2015-05-28
CA2917209A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
MX2016001096A (es) Sales de dasatinib en forma amorfa.
MX2016001095A (es) Sales de dasatinib en forma cristalina.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
EA201792071A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
PH12019500822A1 (en) Crystalline forms of eravacycline
MX337721B (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
MA39715A (fr) Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation
WO2015042414A8 (en) Multicyclic compounds and methods of using same
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
UA111334C2 (uk) Дельта-кристалічна форма аргінінової солі периндроприлу, спосіб її одержання і фармацевтична композиція, яка її містить
EA201591704A1 (ru) Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии
BR112015023222A2 (pt) compostos tetraidroisoquinolin-2-il-(quinazolin-4-il)metanona como inibidores do crescimento de células cancerosas